BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan. Intern Med 2017;56:2993-3001. [PMID: 28943585 DOI: 10.2169/internalmedicine.9033-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Bellos I, Kontzoglou K, Perrea DN. Predictors of tolvaptan short-term response in patients with refractory ascites: A meta-analysis. J Gastroenterol Hepatol 2020;35:182-91. [PMID: 31323125 DOI: 10.1111/jgh.14784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Wang RR, Gu HQ, Wei YY, Yang JX, Hou YX, Liu HM, Yang ZY, Wang XB, Jiang YY. Development and Validation of a Prognostic Model for One-year Survival of Cirrhosis Patients with First-ever Spontaneous Bacterial Peritonitis. J Clin Transl Hepatol 2021;9:647-54. [PMID: 34722179 DOI: 10.14218/JCTH.2021.00031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia. Intern Med 2018;57:2451-8. [PMID: 29607963 DOI: 10.2169/internalmedicine.0629-17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Yada T, Inada Y, Sakamoto H, Higashi H, Kubozono O, Maenohara S, Ido A. Effect of tolvaptan on the prognosis of patients with hepatic ascites. Hepatol Res 2019;49:765-77. [PMID: 30916842 DOI: 10.1111/hepr.13337] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tajiri K, Tokimitsu Y, Ito H, Atarashi Y, Kawai K, Minemura M, Yasumura S, Takahara T, Shimizu Y, Sugiyama T. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis. Dig Dis 2018;36:314-21. [PMID: 29852495 DOI: 10.1159/000489258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
6 Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, Liebe R, Weng H, Ding HG. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterol 2018;18:137. [PMID: 30180806 DOI: 10.1186/s12876-018-0857-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
7 Kogiso T, Sagawa T, Kodama K, Taniai M, Tokushige K. Impact of continued administration of tolvaptan on cirrhotic patients with ascites. BMC Pharmacol Toxicol 2018;19:87. [PMID: 30563565 DOI: 10.1186/s40360-018-0277-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 Nagayama I, Masuda T, Nakagawa S, Murakami T, Ohara K, Matsuoka R, Kobayashi T, Maeshima A, Akimoto T, Saito O, Muto S, Nagata D. Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease. Intern Med 2019;58:1587-91. [PMID: 30713322 DOI: 10.2169/internalmedicine.2174-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]